PO.CL12.01 · 临床研究

Integrated morphometric and molecular classification of central nervous system cancers in 10 seconds using a unified platform with picosecond infrared laser mass spectrometry

编号 3883 展板 16 时间 4/20 02:00–05:00 区域 Section 46 主讲 Arash Zarrine-Afsar, D Phil
分会场 Molecular Classification and Tumor Biology in Cancer
该海报暂无可访问的完整资料 AACR 官方页面 ↗

作者与单位

Alexa Nina Fiorante1, Michael Woolman1, David Munoz2, Farshad Nassiri3, Gelareh Zadeh4, Sunit Das2, Howard Ginsberg2, Arash Zarrine-Afsar3

1University of Toronto, Toronto, ON, Canada,2Unity Health, St. Michael's Hospital, Toronto, ON, Canada,3UHN Princess Margaret Cancer Centre, Toronto, ON, Canada,4UHN Princess Margaret Cancer Centre, Toronto, ON, Canada, Toronto, ON, Canada

摘要 Abstract

The World Health Organization (WHO) now advocates for an integrated approach in the diagnosis of Central Nervous System (CNS) cancers. However, the proposed WHO workflow is complex, relying heavily on multiple instruments-like genetic sequencers and immunohistochemistry scanners-with variable, often lengthy, turnaround times. Leveraging the link between lipid metabolism and cancer, we demonstrate that Picosecond InfraRed Laser Mass Spectrometry (PIRL-MS) can profile the tissue lipidome in just 10 seconds, achieving over 80% sensitivity and specificity for CNS tumor type prediction. This was validated across a large cohort of 150 pediatric (3 morphometrically distinct types, 7 molecular classes) and 1,142 adult (24 morphometric, 8 molecular classes) brain tumour types. While initial results provided strong classification, falling short of robust diagnostic criteria, the ongoing incorporation of machine learning has increased sensitivity and specificity to over 94% in select cases. The capabilities of PIRL-MS to deliver a 10-second diagnosis-based on downstream phenomic (lipidomic) changes-for both morphologically and molecularly distinct tumor (sub)types (e.g., IDH mutation status, medulloblastoma subgroups) offers a clear path toward a unified diagnostic platform. This approach can integrate morphometric and molecular diagnoses on a single instrument in seconds, drastically reducing the need for tissue manipulation and lengthy preparation steps, a feat unmatched by current methods.
利益披露 Disclosure
M. Woolman, Point Surgical Inc. Independent Contractor, Other Securities, Patent. D. Munoz, None.. F. Nassiri, None.. G. Zadeh, None. S. Das, Congress of Neurological Surgeons Travel, Other, Speaker. American Association of Neurosurgery Travel, Other, Speaker. Provincial Lead for CNS Oncology at Ontario Health (Cancer Care Ontario) Independent Contractor, Other, Receives Stipend. VPIX Medical. ). Synaptive ). Cure51 ). Oxford University Press Other, Royalties. Subcortical Surgery Group Advisory board. H. Ginsberg, Point Surgical Inc. g., Board of Directors, non-salaried role), Other Securities, Patent. A. Zarrine-Afsar, Point Surgical Inc. g., Board of Directors, non-salaried role), Independent Contractor, Other Securities, Patent. Waters Corporation Travel. Japan Society for Medical Mass Spectrometry Travel. Brazilian Society for Mass Spectrometry Travel.

在会议检索中打开